Electra Therapeutics raises $350M in upsized IPO
The inflammation biotech's listing adds to a wave of large biotech IPOs not seen since 2021.
Electra Therapeutics, an inflammation-focused biotech, raised $350 million in its initial public offering on Nasdaq. Both Fierce Biotech and BioPharma Dive report the same figure, and both note the offering was upsized, meaning Electra sold more shares or priced above its original range.
The listing is part of a broader surge in biotech IPOs. BioPharma Dive adds that nearly a dozen biotech companies have matched or exceeded $300 million in their 2026 IPOs, a level of large new stock sales not seen since 2021. Fierce Biotech similarly describes Electra as the latest biotech to overshoot its own IPO expectations this year.
While the two sources agree on the core facts, BioPharma Dive provides the wider market context, whereas Fierce Biotech focuses more on Electra's individual positioning. Neither source specifies what Electra plans to do with the proceeds beyond general corporate purposes.
Sources · 3
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.